A multicenter randomized controlled trial (RCT) of 466 patients with more than 5 years of RA with stable disease of at least 6 months suggested that patients with DMARDs gained no additional benefit in inflammation levels, such as C-reactive protein (CRP) levels [4]. This evidence concerns the gene CRP and rheumatoid arthritis.